WINDLAS BIOTECH LIMITED

CERTIFICATE OF ANALYSIS FOR FINISHED PRODUCT			
Product Name	ATORVAHEAL 10 TABLET (SALE)		
Generic Name/Dosage Form Strength (mg)	Atorvastatin Tablets IP 10 mg		
Batch No.	AVU26003	**A.R. No.**	QC/FG/26/07346
Batch Size	150000 STRIP	**Pack Size**	01 X 10 TABLET
Mfg. Date	05/2026	**Exp. Date**	04/2028
Reference	I.P	**Market**	Domestic
Sample Received on	28/05/2026	**Sample Qty.**	1x125 TABLET
Ref. STP No.	WBL/STP/FG/0418	**Ref. SPS No.**	WBL/FPS/FG/8473
Date of Analysis started on	03/06/2026	**Date of Analysis completed on**	19/06/2026
Page No.	01 of 03		

S.No.	Test	Specification	Result
1	Description	White to off white coloured, round, biconvex, film coated tablets, plain on both sides.	White coloured, round, biconvex, film coated tablets, plain on both sides.
2	Identification	In the Assay, the principal peak in the chromatogram obtained with the test solution corresponds to the peak in the chromatogram obtained with the reference solution.	Complies
3	Disintegration Time	Not more than 30 minutes	01 min 06 sec
4	Average weight	93.10 to 102.90 mg	99.3 mg
5	Uniformity of weight	Not more than 2 tablets in 20 deviates from the average weight by more than 10%. No tablet deviates from the average weight by more than 15%.	-3.82% to +2.17%

	Prepared By-QC	Checked By-QC	Reviewed By-Lab.-QA	Approved By-Head-QC/Designee
Name	Aman Kamboj	Ravi Kumar	Rajeev Kumar	Jogendra Singh
Designation	Trainee	Assistant Manager	Sr. Executive	G. M.
Date	19/06/2026	19/06/2026	20/06/2026	20/06/2026

WINDLAS BIOTECH LIMITED

CERTIFICATE OF ANALYSIS FOR FINISHED PRODUCT			
Product Name	ATORVAHEAL 10 TABLET (SALE)		
Generic Name/Dosage Form Strength (mg)	Atorvastatin Tablets IP 10 mg		
Batch No.	AVU26003	**A.R. No.**	QC/FG/26/07346
Batch Size	150000 STRIP	**Pack Size**	01 X 10 TABLET
Mfg. Date	05/2026	**Exp. Date**	04/2028
Reference	I.P	**Market**	Domestic
Sample Received on	28/05/2026	**Sample Qty.**	1x125 TABLET
Ref. STP No.	WBL/STP/FG/0418	**Ref. SPS No.**	WBL/FPS/FG/8473
Date of Analysis started on	03/06/2026	**Date of Analysis completed on**	19/06/2026
Page No.	02 of 03		

S.No.	Test	Specification	Result
6	Dissolution	Not less than 80% (Q) of labeled amount in 30 minutes Stage: S1 Number tested: 6 Each unit is not less than Q+5 percent of the labelled content. Stage: S2 Number tested: 6 Average of 12 units (S1+S2) is equal to or greater than Q, and no unit is less than Q-15 percent of the labelled content. Stage: S3 Number tested: 12 Average of 24 units (S1+S2+S3) is equal to or greater than Q, not more than 2 units are less than Q-15 percent of the labelled content and no unit is less than Q-25 percent of the labelled content.	Min-96.6% Max-102.7% Avg-100.5%
7	Uniformity of Dosage Unit (By Content uniformity)	Acceptance value should be less than 15.	10.91
8	Related substances		
8a.	Atorvastatin pyrrolidone analog impurity	Not more than 0.5 %	0.022%

	Prepared By-QC	Checked By-QC	Reviewed By-Lab.-QA	Approved By-Head-QC/Designee
Name	Aman Kamboj	Ravi Kumar	Rajeev Kumar	Jogendra Singh
Designation	Trainee	Assistant Manager	Sr. Executive	G. M.
Date	19/06/2026	19/06/2026	20/06/2026	20/06/2026

Printed By: Rajveer Singh Date & Time : 20/06/2026 17:48:52 Copy No. 1

This is a electronically signed document, hence does not require any signatures

Format No. : QC/CM/013/F/12-01

WINDLAS BIOTECH LIMITED

CERTIFICATE OF ANALYSIS FOR FINISHED PRODUCT			
Product Name	ATORVAHEAL 10 TABLET (SALE)		
Generic Name/Dosage Form Strength (mg)	Atorvastatin Tablets IP 10 mg		
Batch No.	AVU26003	**A.R. No.**	QC/FG/26/07346
Batch Size	150000 STRIP	**Pack Size**	01 X 10 TABLET
Mfg. Date	05/2026	**Exp. Date**	04/2028
Reference	I.P	**Market**	Domestic
Sample Received on	28/05/2026	**Sample Qty.**	1x125 TABLET
Ref. STP No.	WBL/STP/FG/0418	**Ref. SPS No.**	WBL/FPS/FG/8473
Date of Analysis started on	03/06/2026	**Date of Analysis completed on**	19/06/2026
Page No.	03 of 03		

S.No.	Test	Specification	Result
8b.	Atorvastatin epoxy pyrrolooxazin 6-hydroxy analog impurity	Not more than 0.5 %	0.120%
8c.	Atorvastatin Related Compound D impurity	Not more than 0.5 %	0.033%
8d.	Atorvastatin Related Compound H Impurity	Not more than 1.0 %	Not Detected
8e.	Atorvastatin epoxy pyrrolooxazin 7-hydroxy analog impurity	Not more than 1.0 %	Not Detected
8f.	Atorvastatin epoxy THF analog impurity	Not more than 1.0 %	Not Detected
8g.	Any other secondary impurity	Not more than 0.2 %	0.028%
8h.	Total impurity	Not more than 4.0 %	0.268%
9	Assay Each film coated tablet contains:		
9a.	Atorvastatin Calcium IP eq. to Atorvastatin...10mg	90.0 to 110.0%	98.7%

Remarks : In the opinion of undersigned the sample refer to above specifications complies with I.P

	Prepared By-QC	Checked By-QC	Reviewed By-Lab.-QA	Approved By-Head-QC/Designee
Name	Aman Kamboj	Ravi Kumar	Rajeev Kumar	Jogendra Singh
Designation	Trainee	Assistant Manager	Sr. Executive	G. M.
Date	19/06/2026	19/06/2026	20/06/2026	20/06/2026